Precision medicine clarity, NIH/FDA gains: 'Cures' update
This article was originally published in Scrip
Executive Summary
A third version of the 21st Century Cures Act, unveiled on 13 May, brought new clarity to some of the provisions affecting the National Institutes of Health (NIH) and the FDA – most notably, the precision medicine measures, which started out in the first draft with a simple place holder.